Prostate-Specific Antigen

A new blood test called Stockholm3 detects 90% of aggressive prostate cancer cases, outperforming the traditional PSA test which detects 74%. A study involving 12,000 men found Stockholm3 missed significantly fewer serious cases without increasing unnecessary follow-ups.

A multicomponent blood-based biomarker test combining prostate-specific antigen (PSA), plasma protein biomarkers, a polygenic risk score, and clinical variables outperforms PSA alone in identifying clinically significant prostate cancers. The test integrates multiple factors to improve detection accuracy beyond traditional PSA screening.

PSA testing for prostate cancer is controversial due to its potential for false positives and inability to distinguish between life-threatening and non-threatening cancers. Experts like Dr. Christopher Warlick highlight that elevated PSA levels can result from noncancerous conditions, and the United States Preventive Services Task Force recommends men aged 55-69 discuss screening with their providers, particularly those at higher risk such as African American men or those with family histories of prostate cancer.

A landmark review has confirmed that prostate cancer screening is effective in saving lives. The review highlights the importance of early detection and treatment. Prostate cancer screening has been shown to reduce mortality rates.